| |||||||||
|
Glaucoma
Awareness Month Emphasizes Treatments That Reduce Side Effects, Help Save Vision During
Glaucoma Awareness Month in January, the National Eye Health Education Program (NEHEP)
Partnership, coordinated by the National Eye Institute (NEI), is highlighting
the medical advances for glaucoma that have been developed during the past five
years. "These
therapies effectively treat glaucoma while at the same time greatly reducing
side effects," said Jack A. McLaughlin, Ph.D, acting director of the NEI,
one of the Federal government's National Institutes of Health. Glaucoma,
a leading cause of irreversible vision loss in the United States, is a disease
that affects three million Americans, half of whom do not know they have it
because of its lack of early symptoms. Advances in glaucoma treatment are only
beneficial when the disease is detected early. By the time people realize they
are losing vision, the vision they have already lost is gone forever. Those in
higher risk groups should get a dilated eye exam -- in which drops are placed in
the eye to dilate the pupils -- at least every two years. A dilated eye exam
allows the eye care professional to obtain a better view of the eye's optic
nerve to look for early signs of glaucoma. Higher risk groups include anyone
over the age of 60; African Americans over the age of 40; and people who have a
family history of glaucoma. Two new
glaucoma drugs -- latanoprost and dorzolamide -- based on NEI-supported
research, "reduce unpleasant side effects, such as dry eyes and increased
risk of retinal detachment," Dr. McLaughlin said. "The side effects
from the older glaucoma treatments were major reasons why some glaucoma patients
did not take their medications. The new therapies help preserve remaining vision
and mark a significant step in improving the quality of life for people with
glaucoma." Glaucoma
occurs when nourishing fluid that normally flows in and out of the eye drains
too slowly. As the fluid builds up, the pressure inside the eye progressively
increases. This leads to optic nerve damage and reduced peripheral (side)
vision. As the disease worsens, the field of vision gradually narrows and
blindness may result. However, if glaucoma is detected and treated early in its
progression, it can usually be slowed and serious vision loss can be delayed. Dr.
McLaughlin also noted that NEI-supported research has shown that laser surgery
is a safe and effective alternative to eye drops as a treatment for
newly-diagnosed glaucoma. Laser surgery for glaucoma involves using a high
energy beam of light to make tiny, evenly-spaced burns that open up the drainage
area inside the eye, allowing for better outflow of the fluid. This procedure,
often done in the doctor's office, requires only local anesthesia. One of
the more significant recent research findings was that Black and White patients
with advanced glaucoma respond differently to two surgical treatments for the
disease. Scientists found that Black patients with advanced glaucoma benefit
more from a regimen that begins with laser surgery, and Whites patients benefit
more from one that begins with an operation called a trabeculectomy. With this
procedure, a small opening is made in the front chamber of the eye, providing a
new drainage pathway for the fluid inside the eye. A trabeculectomy is done in
an operating room and requires local or general anesthesia. "This
was the first evidence that unique patient characteristics could influence our
therapeutic choices for glaucoma," said Eve Higginbotham, MD, chairperson
of the NEHEP Planning Committee and chairperson of the Department of
Ophthalmology at the University of Maryland. "Doctors now have better
information to recommend treatment programs, depending on the patient's race,
and give people with advanced glaucoma a better chance to preserve and prolong
their vision." Glaucoma is three to four times as common in Blacks as in
Whites, and blindness from glaucoma is six times more common in Blacks than in
Whites. Glaucoma
Awareness Month is sponsored by the NEHEP Partnership, which represents public
and private organizations dedicated to educating the public about the importance
of preventive eye care. The
National Eye Institute (NEI) is part of the National Institutes of Health (NIH)
and is the Federal government's lead agency for vision research. NEI-supported
research leads to sight-saving treatments and plays a key role in reducing
visual impairment and blindness. The NIH is an agency of the US Department of
Health and Human Services. |